Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.
Identifieur interne : 001547 ( PubMed/Corpus ); précédent : 001546; suivant : 001548Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.
Auteurs : Mia Kumar ; Steven Mazur ; Britini L. Ork ; Elena Postnikova ; Lisa E. Hensley ; Peter B. Jahrling ; Reed Johnson ; Michael R. HolbrookSource :
- Journal of virological methods [ 1879-0984 ] ; 2015.
English descriptors
- KwdEn :
- Animals, Anti-Infective Agents, Containment of Biohazards, Gamma Rays, Humans, Microbial Viability (drug effects), Microbial Viability (radiation effects), Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (physiology), Middle East Respiratory Syndrome Coronavirus (radiation effects), Time Factors, Virus Inactivation.
- MESH :
- chemical : Anti-Infective Agents.
- drug effects : Microbial Viability, Middle East Respiratory Syndrome Coronavirus.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- radiation effects : Microbial Viability, Middle East Respiratory Syndrome Coronavirus.
- Animals, Containment of Biohazards, Gamma Rays, Humans, Time Factors, Virus Inactivation.
Abstract
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a recently emerged virus that has caused a number of human infections and deaths, primarily in the Middle East. The transmission of MERS-CoV to humans has been proposed to be as a result of contact with camels, but evidence of human-to-human transmission also exists. In order to work with MERS-CoV in a laboratory setting, the US Centers for Disease Control and Prevention (CDC) has determined that MERS-CoV should be handled at a biosafety level (BSL) 3 (BSL-3) biocontainment level. Many processes and procedures used to characterize MERS-CoV and to evaluate samples from MERS-CoV infected animals are more easily and efficiently completed at BSL-2 or lower containment. In order to complete experimental work at BSL-2, demonstration or proof of inactivation is required before removal of specimens from biocontainment laboratories. In the studies presented here, we evaluated typical means of inactivating viruses prior to handling specimens at a lower biocontainment level. We found that Trizol, AVL buffer and gamma irradiation were effective at inactivating MERS-CoV, that formaldehyde-based solutions required at least 30 min of contact time in a cell culture system while a mixture of methanol and acetone required 60 min to inactivate MERS-CoV. Together, these data provide a foundation for safely inactivating MERS-CoV, and potentially other coronaviruses, prior to removal from biocontainment facilities.
DOI: 10.1016/j.jviromet.2015.07.002
PubMed: 26190637
Links to Exploration step
pubmed:26190637Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.</title><author><name sortKey="Kumar, Mia" sort="Kumar, Mia" uniqKey="Kumar M" first="Mia" last="Kumar">Mia Kumar</name><affiliation><nlm:affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Mazur, Steven" sort="Mazur, Steven" uniqKey="Mazur S" first="Steven" last="Mazur">Steven Mazur</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Ork, Britini L" sort="Ork, Britini L" uniqKey="Ork B" first="Britini L" last="Ork">Britini L. Ork</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Postnikova, Elena" sort="Postnikova, Elena" uniqKey="Postnikova E" first="Elena" last="Postnikova">Elena Postnikova</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name><affiliation><nlm:affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States; NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Johnson, Reed" sort="Johnson, Reed" uniqKey="Johnson R" first="Reed" last="Johnson">Reed Johnson</name><affiliation><nlm:affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R" last="Holbrook">Michael R. Holbrook</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States. Electronic address: michael.holbrook@nih.gov.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26190637</idno><idno type="pmid">26190637</idno><idno type="doi">10.1016/j.jviromet.2015.07.002</idno><idno type="wicri:Area/PubMed/Corpus">001547</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001547</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.</title><author><name sortKey="Kumar, Mia" sort="Kumar, Mia" uniqKey="Kumar M" first="Mia" last="Kumar">Mia Kumar</name><affiliation><nlm:affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Mazur, Steven" sort="Mazur, Steven" uniqKey="Mazur S" first="Steven" last="Mazur">Steven Mazur</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Ork, Britini L" sort="Ork, Britini L" uniqKey="Ork B" first="Britini L" last="Ork">Britini L. Ork</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Postnikova, Elena" sort="Postnikova, Elena" uniqKey="Postnikova E" first="Elena" last="Postnikova">Elena Postnikova</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E" last="Hensley">Lisa E. Hensley</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B" last="Jahrling">Peter B. Jahrling</name><affiliation><nlm:affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States; NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Johnson, Reed" sort="Johnson, Reed" uniqKey="Johnson R" first="Reed" last="Johnson">Reed Johnson</name><affiliation><nlm:affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R" last="Holbrook">Michael R. Holbrook</name><affiliation><nlm:affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States. Electronic address: michael.holbrook@nih.gov.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of virological methods</title><idno type="eISSN">1879-0984</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Infective Agents</term><term>Containment of Biohazards</term><term>Gamma Rays</term><term>Humans</term><term>Microbial Viability (drug effects)</term><term>Microbial Viability (radiation effects)</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Middle East Respiratory Syndrome Coronavirus (physiology)</term><term>Middle East Respiratory Syndrome Coronavirus (radiation effects)</term><term>Time Factors</term><term>Virus Inactivation</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microbial Viability</term><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Microbial Viability</term><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Containment of Biohazards</term><term>Gamma Rays</term><term>Humans</term><term>Time Factors</term><term>Virus Inactivation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a recently emerged virus that has caused a number of human infections and deaths, primarily in the Middle East. The transmission of MERS-CoV to humans has been proposed to be as a result of contact with camels, but evidence of human-to-human transmission also exists. In order to work with MERS-CoV in a laboratory setting, the US Centers for Disease Control and Prevention (CDC) has determined that MERS-CoV should be handled at a biosafety level (BSL) 3 (BSL-3) biocontainment level. Many processes and procedures used to characterize MERS-CoV and to evaluate samples from MERS-CoV infected animals are more easily and efficiently completed at BSL-2 or lower containment. In order to complete experimental work at BSL-2, demonstration or proof of inactivation is required before removal of specimens from biocontainment laboratories. In the studies presented here, we evaluated typical means of inactivating viruses prior to handling specimens at a lower biocontainment level. We found that Trizol, AVL buffer and gamma irradiation were effective at inactivating MERS-CoV, that formaldehyde-based solutions required at least 30 min of contact time in a cell culture system while a mixture of methanol and acetone required 60 min to inactivate MERS-CoV. Together, these data provide a foundation for safely inactivating MERS-CoV, and potentially other coronaviruses, prior to removal from biocontainment facilities.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26190637</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>223</Volume><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J. Virol. Methods</ISOAbbreviation></Journal><ArticleTitle>Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.</ArticleTitle><Pagination><MedlinePgn>13-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jviromet.2015.07.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-0934(15)00235-9</ELocationID><Abstract><AbstractText>Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a recently emerged virus that has caused a number of human infections and deaths, primarily in the Middle East. The transmission of MERS-CoV to humans has been proposed to be as a result of contact with camels, but evidence of human-to-human transmission also exists. In order to work with MERS-CoV in a laboratory setting, the US Centers for Disease Control and Prevention (CDC) has determined that MERS-CoV should be handled at a biosafety level (BSL) 3 (BSL-3) biocontainment level. Many processes and procedures used to characterize MERS-CoV and to evaluate samples from MERS-CoV infected animals are more easily and efficiently completed at BSL-2 or lower containment. In order to complete experimental work at BSL-2, demonstration or proof of inactivation is required before removal of specimens from biocontainment laboratories. In the studies presented here, we evaluated typical means of inactivating viruses prior to handling specimens at a lower biocontainment level. We found that Trizol, AVL buffer and gamma irradiation were effective at inactivating MERS-CoV, that formaldehyde-based solutions required at least 30 min of contact time in a cell culture system while a mixture of methanol and acetone required 60 min to inactivate MERS-CoV. Together, these data provide a foundation for safely inactivating MERS-CoV, and potentially other coronaviruses, prior to removal from biocontainment facilities.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazur</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ork</LastName><ForeName>Britini L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postnikova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hensley</LastName><ForeName>Lisa E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahrling</LastName><ForeName>Peter B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States; NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Reed</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holbrook</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>NIAID Integrated Research Facility, Ft. Detrick, Frederick, MD, United States. Electronic address: michael.holbrook@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272200700016I</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AI999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN2722007000161</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="Y">Anti-Infective Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003264" MajorTopicYN="N">Containment of Biohazards</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005720" MajorTopicYN="Y">Gamma Rays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050296" MajorTopicYN="N">Microbial Viability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038301" MajorTopicYN="Y">Virus Inactivation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Fixation</Keyword><Keyword MajorTopicYN="N">Inactivation</Keyword><Keyword MajorTopicYN="N">Irradiation</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26190637</ArticleId><ArticleId IdType="pii">S0166-0934(15)00235-9</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2015.07.002</ArticleId><ArticleId IdType="pmc">PMC4555185</ArticleId><ArticleId IdType="mid">NIHMS709372</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Jul;20(7):1231-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24964193</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(7):e69127</Citation><ArticleIdList><ArticleId IdType="pubmed">23844250</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2014 Sep;8(5):585-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25074677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ultramicroscopy. 2004 Aug;100(3-4):153-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15231305</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2004 Oct;121(1):85-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15350737</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2004 Aug;119(2):195-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15158603</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation><ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId></ArticleIdList></Reference><Reference><Citation>Biologicals. 2005 Jun;33(2):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15939287</ArticleId></ArticleIdList></Reference><Reference><Citation>East Mediterr Health J. 2013;19 Suppl 1:S12-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23888790</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermatology. 2006;212 Suppl 1:119-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16490989</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603</Citation><ArticleIdList><ArticleId IdType="pubmed">24062443</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2014 Feb;95(Pt 2):408-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24197535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Infect. 2005 Oct;61(2):107-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15923059</ArticleId></ArticleIdList></Reference><Reference><Citation>J Oral Maxillofac Pathol. 2012 Sep;16(3):400-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23248474</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2006 Oct;46(10):1770-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17002634</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012;17(39). pii: 20285</Citation><ArticleIdList><ArticleId IdType="pubmed">23041020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001547 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001547 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26190637
|texte= Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26190637" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |